Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:10/26/2007

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 14 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 23,600 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. Sonic Foundry reports GAAP loss as Q2 revenues rise
4. Fiserv reports $113.5 million in Q1 profit
5. Third Wave reports net loss of $18.9M for 2006
6. Musicnotes reports 45 percent growth in 2006
7. Sonic Foundry reports net loss, higher revenue
8. Sonic Foundry reports first cash-positive quarter
9. Merge Healthcare reports $10.8M net loss in Q3
10. Third Wave reports $5.2M third quarter loss
11. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the "Company"), ... of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... introduce cutting edge communication technology, provide continued education ... This webinar series demonstrates online communication features and ... web conferencing’s most innovative and powerful tools. , ...
(Date:12/24/2014)... December 23, 2014 Nashville Fertility Center announced ... for the American Society for Reproductive Medicine (ASRM), a leading ... medicine. In his new role as treasurer, Dr. Hill ... have a voice in furthering the mission of ASRM. ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... Food and Drug Administration (FDA) regarding a Special Protocol ...
... - OncoGenex Pharmaceuticals (NASDAQ: OGXI ) announced today ... Thursday, August 6, 2009. OncoGenex will host a conference call ... discuss quarterly results. , The webcast can be accessed on ... www.oncogenex.com . Alternatively, you may access the live conference ...
... The years of ... big breakthrough in the search for a viable alternative feedstock for biodiesel in combination with ... happy to announce the much awaited commercial release of Couple oil crop cultivation (COC) technology. ... (PRWEB) August 3, 2009 ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 4Jatropha Couple Oil Crop Cultivation Technology Commercially Released 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 3
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ... the "Global Wearable Technologies Market and Applications, ... Trends and Forecast 2014-2020" report to their ... smart devices that can be worn on the ...
(Date:1/22/2015)... has launched its new NXG series of time clocks with ... higher standard for collecting attendance and labor data and complements ... touch screen interface and seamless connection to cloud-based iSolved, the ... for the small to mid-size employer. The G2 ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... virtual reality forest, will anyone hear an environmental message? They ... the make-believe redwood. New findings from Stanford researchers show that ... to saw through a towering sequoia until it crashed in front ... people who only imagined what it,s like to cut down a ...
... will present techniques and discuss surgical approaches and applications ... Association of Neurological Surgeons (AANS), held April 9-13, 2011 ... The Department of Neurosurgery at NYU Langone Medical Center ... hospitals in the country for neurology and neurosurgery by ...
... Mohammad Golabi, a soil science professor at the University of ... to practical use in shielding the reefs in Pago Bay ... of the major health hazards facing Guam,s reefs is soil ... that make up a reef system. "Vetiver,s ability to tolerate ...
Cached Biology News:Stanford's virtual reality lab focuses on conservation 2Stanford's virtual reality lab focuses on conservation 3NYU Langone experts present advances at American Association of Neurological Surgeons Meeting 2Bioengineering with vetiver grass on Guam 2
Ultra-sensitive, non-radioactive detection of rat Big Endothelin-1 (Big ET-1)...
Request Info...
Request Info...
Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
Biology Products: